As of 2024-12-15, the Relative Valuation of CytomX Therapeutics Inc (CTMX) is 2.04 USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.11 USD, the upside of CytomX Therapeutics Inc based on Relative Valuation is 83.9%.
The range of the Relative Valuation is 1.00 - 4.87 USD.
| Range | Selected | |
| Trailing P/E multiples | 16.9x - 27.6x | 17.3x |
| Forward P/E multiples | 18.9x - 20.4x | 19.4x |
| Fair Price | 1.00 - 4.87 | 2.04 |
| Upside | -10.2% - 338.8% | 83.9% |
| Date | P/E |
| 2024-12-13 | 6.28 |
| 2024-12-12 | 6.34 |
| 2024-12-11 | 6.68 |
| 2024-12-10 | 6.85 |
| 2024-12-09 | 7.13 |
| 2024-12-06 | 6.68 |
| 2024-12-05 | 6.56 |
| 2024-12-04 | 7.30 |
| 2024-12-03 | 6.96 |
| 2024-12-02 | 6.17 |
| 2024-11-29 | 6.00 |
| 2024-11-27 | 5.77 |
| 2024-11-26 | 5.77 |
| 2024-11-25 | 5.43 |
| 2024-11-22 | 5.04 |
| 2024-11-21 | 4.90 |
| 2024-11-20 | 4.92 |
| 2024-11-19 | 5.05 |
| 2024-11-18 | 4.88 |
| 2024-11-15 | 5.15 |
| 2024-11-14 | 5.66 |
| 2024-11-13 | 5.72 |
| 2024-11-12 | 5.89 |
| 2024-11-11 | 5.89 |
| 2024-11-08 | 6.17 |
| 2024-11-07 | 5.66 |
| 2024-11-06 | 5.66 |
| 2024-11-05 | 5.62 |
| 2024-11-04 | 5.72 |
| 2024-11-01 | 5.94 |
| 2024-10-31 | 5.63 |
| 2024-10-30 | 5.61 |
| 2024-10-29 | 5.65 |
| 2024-10-28 | 5.72 |
| 2024-10-25 | 5.83 |
| 2024-10-24 | 6.11 |
| 2024-10-23 | 6.11 |
| 2024-10-22 | 6.22 |
| 2024-10-21 | 6.56 |
| 2024-10-18 | 6.68 |
| 2024-10-17 | 6.56 |
| 2024-10-16 | 6.68 |
| 2024-10-15 | 6.34 |
| 2024-10-14 | 6.17 |
| 2024-10-11 | 6.51 |
| 2024-10-10 | 6.34 |
| 2024-10-09 | 6.51 |
| 2024-10-08 | 6.45 |
| 2024-10-07 | 6.62 |
| 2024-10-04 | 6.51 |